The American Cancer Society tracks survival rates for 22 types of localized cancer, including the most common in the US: prostate (100%), skin (99.6% five-year survival rate), breast (99.3%), lung (65 ...

Swiss pharma giant Roche today released financial results for the first nine months of 2025, showing that group sales grew by ...

A Fermanagh woman says a routine breast cancer screening at the Lakeland Forum may have saved her life, after it revealed a tumour she would ...

Swiss pharma giant Roche Holding AG RHHBY reported sales of CHF 14.9 billion for the third quarter of 2025, up 6% year over ...

For the first nine months of 2025, Roche’s overall sales grew 7% at constant currencies to 45.9 billion Swiss francs (nearly ...

Investing.com -- Swiss drugmaker Roche Holding AG (SIX: ROG) on Thursday raised its full-year profit outlook after reporting ...

Group sales In the first nine months of 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 45.9 billion due to strong demand for our pharmaceutical and diagnostic products.

Amid steady Q3 growth, Roche's giredestrant-Afinitor combo extended survival in advanced ER-positive, HER2-negative early breast cancer.

In the study, researchers molecularly screened nearly 2,000 cancer patients and matched 14 percent into a study arm.

This is the gap that has been flagged by the latest Lancet study, which shows that compared to high income countries, where ...